0.00
price down icon100.00%   -11.13
after-market Dopo l'orario di chiusura: 11.20 11.20 +
loading

Verve Therapeutics Inc Borsa (VERV) Ultime notizie

pulisher
09:17 AM

Eli Lilly (LLY) Completes Acquisition of Verve Therapeutics | LL - GuruFocus

09:17 AM
pulisher
09:15 AM

Is Verve Therapeutics Inc. a good long term investmentExplosive returns - Autocar Professional

09:15 AM
pulisher
09:14 AM

Lilly completes acquisition of Verve Therapeutics to advance one - GuruFocus

09:14 AM
pulisher
09:04 AM

Lilly Completes Acquisition Of Verve Therapeutics - Nasdaq

09:04 AM
pulisher
08:58 AM

Eli Lilly completes acquisition of Verve Therapeutics - TipRanks

08:58 AM
pulisher
08:52 AM

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk | Eli Lilly and Company - Eli Lilly and Company

08:52 AM
pulisher
08:52 AM

Lilly completes Verve Therapeutics acquisition for cardiovascular treatments - StreetInsider

08:52 AM
pulisher
08:49 AM

Lilly Acquires Verve Therapeutics, Targets One-Time Cardiovascular Treatment | LLY Stock News - Stock Titan

08:49 AM
pulisher
07:38 AM

Verve Therapeutics Inc. Stock Analysis and ForecastPhenomenal wealth increase - PrintWeekIndia

07:38 AM
pulisher
Jul 24, 2025

Lilly completes tender offer for Verve Therapeutics shares - Investing.com

Jul 24, 2025
pulisher
Jul 24, 2025

Lilly and Verve announce expiration of Verve tender offer | Eli Lilly and Company - Eli Lilly

Jul 24, 2025
pulisher
Jul 24, 2025

Lilly Secures 55.7% of Verve Shares in $10.50 Cash Plus CVR Deal, Closing Set for July 25 - Stock Titan

Jul 24, 2025
pulisher
Jul 23, 2025

Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition - MSN

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Verve Therapeutics Inc. stock priceBreakthrough wealth creation - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B - MSN

Jul 22, 2025
pulisher
Jul 22, 2025

Eli Lilly, Verve Therapeutics receive early termination from US FTC - MLex

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Verve Therapeutics Inc. stockHigh-yield investments - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

(VERV) Trading Advice - news.stocktradersdaily.com

Jul 22, 2025
pulisher
Jul 21, 2025

3 Bullish Biotech Stocks With Explosive Growth Trends - MarketBeat

Jul 21, 2025
pulisher
Jul 19, 2025

Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease - drugdiscoverytrends.com

Jul 19, 2025
pulisher
Jul 19, 2025

Is Verve Therapeutics Inc. stock a good hedge against inflationFree AI-Driven Trading Strategies - beatles.ru

Jul 19, 2025
pulisher
Jul 16, 2025

Lilly’s $1 billion CRISPR bet: what Verve means for gene editing - The Pharma Letter

Jul 16, 2025
pulisher
Jul 15, 2025

Verve Offers $416K Award To GC Amid Lilly Acquisition - Law360

Jul 15, 2025
pulisher
Jul 15, 2025

Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition By Investing.com - Investing.com South Africa

Jul 15, 2025
pulisher
Jul 15, 2025

Verve Therapeutics Announces Retention Bonus Program for Executives - TipRanks

Jul 15, 2025
pulisher
Jul 14, 2025

Why Verve Therapeutics Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru

Jul 14, 2025
pulisher
Jul 13, 2025

Verve Therapeutics, Inc. (VERV): A Bull Case Theory - MSN

Jul 13, 2025
pulisher
Jul 07, 2025

Prime Medicine soars as Jones sees it as an acquisition target - Seeking Alpha

Jul 07, 2025
pulisher
Jul 06, 2025

Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - MSN

Jul 06, 2025
pulisher
Jun 27, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Jun 27, 2025
pulisher
Jun 27, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (NasdaqVERV), Sage Therapeutics, Inc. (NasdaqSAGE), Cantaloupe, Inc. (NasdaqCTLP), Volato Group, Inc. (NYSE American - Morningstar

Jun 27, 2025
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Capitalizzazione:     |  Volume (24 ore):